Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-09
1999-12-21
Dees, Jose' G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514261, 514262, 514263, 544257, 544264, 544265, 544266, 544267, A01N 4354, A01N 4390, C07D47500, C07D47300
Patent
active
060049669
ABSTRACT:
The use of a compound of formula I ##STR1## in which R.sub.1 and R.sub.2 are N, X.sub.1 and X.sub.2 which may be the same or different are hydrogen, hydroxy, or an optionally substituted alkyl, and Z.sub.1 and Z.sub.2 which may be the same or different are hydrogen, hydroxy, keto (.dbd.O), or one of Z.sub.1 and X.sub.1 and Z.sub.2 and X.sub.2 form a second bond of a double bond at the 1,6 or 2,3 positions with the proviso that at least one of the groupings R.sub.1 Z.sub.1 X.sub.1 R.sub.2 Z.sub.2 X.sub.2 and R.sub.1 X.sub.1 Z.sub.2 form a hydroxamate moiety (--N(OH)C(.dbd.O)-- in which R.sub.1 and R.sub.2 is N, Z.sub.1 and/or Z.sub.2 is .dbd.O and X.sub.1 and/or X.sub.2 is OH or R.sub.1 is N, Z.sub.2 is .dbd.O and X.sub.1 is OH and B is a 5 or 6 membered ring of formula II or III ##STR2## in which R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 which may be the same or different are CH or N with the proviso that ring B cannot contain more than 3 ring members which are nitrogen and the ring B may optionally be substituted with a physiologically acceptable organic or inorganic acid, for the manufacture of a medicament for use as an anti-ischaemic agent.
REFERENCES:
patent: 4757078 (1988-07-01), Misra
Lam et al., "Photochemistry of Some Pteridine N-Oxides, "J. Org. Chem., vol. 43, No. 1, pp. 167-168, New York, NY (1978).
Tserng et al., Electron impact-induced fragmentation of 3-hydroxy quinazoline-2,4(1H,3H) dione, J. Heterocycl. Chem. 12 (1), 79-83, 1975.
Murahashi et al., "Tunstate-catalyzed Oxidation . . . ", J. Org. Chem. 55 (1990) 1744-1749.
Myles et al., "Purine N-Oxides", J. Bio. Chem., 244:15 (1969) 4072-4076.
Murahashi et al., "Tungstate-catalyzed Oxidation . . . ", J. Chem. Soc. Chem. Commun. (1987) 1470-1473.
Christie et al., "Cyclisation to Schiff . . . ", J. Chem. Soc. Perkin Trans. 1 (1985) 2779-2783.
Eckstein et al., "A Facile Rearrangement . . . ", Heterocycles 20:10 (1983) 1898-1901.
Dubby et al., "Influence of Some Ionic . . . ", J. Indian Chem. Soc. LIX (1982) 706-709.
Anderson et al., "Increased Incidence of Mammary . . . ", J. Natl. Cancer Inst. 61:6 (1978) 1410-1415.
Lam et al., "Photochemistry of Some . . . ", J. Org. Chem. 43:1 (1978) 167-169.
Parham et al., "Purine N-Oxides . . . ", J. Org. Chem. 36:18 (1971) 2638-2647.
Lion et al., "Nouveaux Decontaminants . . . ", Bull. Soc. Chim. Belg. 100:8 (1991) 616-621.
Parham et al., "Purine N-Oxides . . . ", Liss 32 (1967) 1150-1155.
Fahmy et al., "Novel Synthesis of Pyridopyrimidine Diones", Heterocycles 24:8 (1986) 2200-2213.
Lee et al., "Chemical Reactivities and Oncogenicites . . . " Chem.-Biol. Interactions 25 (1979) 369-373.
DE,A, 23 56 690 (Kohjin Co., Ltd.) May 30, 1974.
J. Clark et al, "Heterocyclic studies. Part IV. The action of hydroxylamine on 4-hydroxypteridine and its methyl derivatives", J. Chem. Soc. (c), vol. 8, 1968, pp. 919-922.
J.A. Montgomery et al. "1-Glycosyl derivatives of 5-aminoimidazole-4-carboxamide", J. Med. Chem., vol. 15, No. 12, 1972.
G.R. Revankar "Synthesis and antiviral activity of certain 5'-monophosphates of 9-D-arabinofuranosyladenine and 9-D-arabinofuranosylhypoxanthine", J. Med. Chem. vol. 18, No. 7, 1975 pp. 721-726.
M.N. Teller et al. "Comparison of the oncogenicites of four structrally isomeric N-hydroxyxanthines", Cancer Res., vol. 38, No. 7, 1978, pp. 2038-2042.
L. Bauer et al. "Pyrazolo-N-hydroxyuracils from the modified Lossen rearrangement of vicinal pyrazoledicarbohydroxamates", J. Heterocycl. Chem., vol. 4 No. 3, 1967, pp. 325-334.
M. Borbil et al., "Molecular orbital calculations for purine-N-oxides", Rev. Roum. Biochim., vol. 15, No. 1, 1978, pp. 3-8.
AN-93-338929, Database WPI Week 9343, Derwent Publications, Ltd. London, GB.
EP, A, 0 237 348 (The Wellcome Foundation Ltd.) Sep. 16, 1987--see page 2.
Lewis Anthony Edward
Singh Surinder
BTG International Limited
Dees Jos,e G.
Pryor Alton
LandOfFree
Use of xanthine oxidase inhibitors as anti-ischaemic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of xanthine oxidase inhibitors as anti-ischaemic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of xanthine oxidase inhibitors as anti-ischaemic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-505417